1
项与 anti-CD19 CAR T-cell therapy ( Acibadem University ) 相关的临床试验Phase I/ II Study of Cluster of Differentiation 19 (CD19) Specific CAR-T Cells (ISIKOK 19) in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL)
It is a treatment that activates and strengthens the immune system against cancer. Recently, T cell receptors have been genetically rearranged by adaptive T cell therapies, which are promising in the fight against cancer, and are now able to recognize antigens on tumor cells. These modified T cell receptors are called chimeric antigen receptors. Many previous clinical studies have shown that different CAR-T cells are effective in relapse / refractory B cell cancers and NHL.
100 项与 anti-CD19 CAR T-cell therapy ( Acibadem University ) 相关的临床结果
100 项与 anti-CD19 CAR T-cell therapy ( Acibadem University ) 相关的转化医学
100 项与 anti-CD19 CAR T-cell therapy ( Acibadem University ) 相关的专利(医药)
100 项与 anti-CD19 CAR T-cell therapy ( Acibadem University ) 相关的药物交易